BioNTech SE Sponsored ADR $BNTX Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1,664.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 365,333 shares of the company’s stock after purchasing an additional 344,630 shares during the period. SG Americas Securities LLC’s holdings in BioNTech were worth $34,780,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dodge & Cox grew its stake in BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after buying an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in BioNTech by 6.7% in the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock valued at $135,800,000 after buying an additional 80,005 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of BioNTech by 5.6% during the second quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after acquiring an additional 35,958 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of BioNTech by 2.8% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 667,635 shares of the company’s stock valued at $71,083,000 after acquiring an additional 18,351 shares during the period. Finally, Candriam S.C.A. grew its position in shares of BioNTech by 0.5% during the third quarter. Candriam S.C.A. now owns 589,452 shares of the company’s stock worth $58,132,000 after acquiring an additional 2,716 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of analyst reports. UBS Group raised shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Morgan Stanley decreased their target price on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, March 10th. HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Stock Performance

BNTX stock opened at $88.77 on Thursday. The company has a market capitalization of $21.30 billion, a P/E ratio of -16.94 and a beta of 1.51. The company has a 50-day simple moving average of $104.54 and a 200 day simple moving average of $101.82. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.